Keywords: لیپاتینیب; Lapatinib; Diabetic rats; Pharmacokinetics; Glycaemia;
مقالات ISI لیپاتینیب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: لیپاتینیب; Cancer stem cells; Cetuximab; Lapatinib; Epidermal growth factor receptor; Oral squamous cell carcinoma; Molecularly-targeted therapy; Sphere formation;
Keywords: لیپاتینیب; Fed state; Protein precipitation; Solid phase extraction; Biorelevantmedia; Drug analysis; Physicochemical properties; ÎCN; acetonitrile; API; active pharmaceutical ingredient; BA/BE; bioavailability/bioequivalence; CV; coefficient of variation; EtOH; et
Keywords: لیپاتینیب; Esophagogastric cancer; HER2; Targeted therapy; Trastuzumab; Pertuzumab; TDM-1; Lapatinib;
Keywords: لیپاتینیب; cancer du sein; cytotoxique; lapatinib; radiothérapie; tamoxifène; thérapie ciblée; trastuzumabbreast cancer; cytotoxic; lapatinib; radiotherapy; tamoxifen; targeted therapy; trastuzumab
Keywords: لیپاتینیب; Cardiomyopathy; Trastuzumab; Lapatinib; Pertuzumab; Breast cancer
Keywords: لیپاتینیب; Lapatinib; Early breast cancer; Adjuvant; Hormone receptor;
Keywords: لیپاتینیب; Lapatinib; Human serum albumin; Drug–protein interaction; Fluorescence quenching; Molecular docking
Keywords: لیپاتینیب; Metastatic breast cancer; HER2; Trastuzumab; Pertuzumab; T-DM1; Lapatinib; Resistance; Management; Novel therapy;
Keywords: لیپاتینیب; Ado-trastuzumab emtansine; CNS metastasis; HER2; Lapatinib; Radiation;
Keywords: لیپاتینیب; Bevacizumab; Lapatinib; Sunitinib; Sorafenib; Rofecoxib; Celecoxib; Venlafaxine; Prednisone Licorice acid; cyclosporin A; Medications; Drug-induced hypertension; Blood pressure; chemicals; Tyrosine kinase inhibitors;
Keywords: لیپاتینیب; Paclitaxel (PubChem CID: 36314); Lapatinib (PubChem CID: 11557040); Pluronic F127 (PubChem CID: 24751); Localized co-delivery; Combination therapy; Thermosensitive gel; Lapatinib; Paclitaxel; Breast cancer;
Keywords: لیپاتینیب; lapatinib; paclitaxel; poorly water-soluble drugs; solubility; micelle; cancer chemotherapy; sensitize; human epidermal growth factor receptor-2; polymeric drug delivery systems; conjugation;
Keywords: لیپاتینیب; Lapatinib; HSA nanoparticle; Triple negative breast cancer; 4T1 cells;
Keywords: لیپاتینیب; Lapatinib; Direct arylation; C-H activation; Pivalic acid; Palladium acetate;
Keywords: لیپاتینیب; Lapatinib; Core–shell nanoparticles; Glioma; Small-molecule inhibitor; Drug delivery
Keywords: لیپاتینیب; Breast cancer; Adverse events; Trastuzumab; Pertuzumab; Lapatinib; Bevacizumab; Trastuzumab-emtansine; Everolimus; ABC; advanced breast cancer; QoL; quality of life; AE; adverse event; HER2; human epidermal growth factor receptor type 2; LVEF; left ventri
Keywords: لیپاتینیب; Pulmonary hypertension; Lapatinib; Tyrosine kinase inhibitors
A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP
Keywords: لیپاتینیب; Lapatinib; Trastuzumab; Beyond progression; PIK3CA; Brain metastasis; Circulating tumor DNA;
Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door
Keywords: لیپاتینیب; Personalised medicine; Targeted therapy; ERBB3; Tyrosine kinase inhibitors; Trastuzumab; Afatinib; Lapatinib;
Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer
Keywords: لیپاتینیب; Breast cancer; Central nervous system (CNS) metastases; HER2; Small-molecule tyrosine kinase inhibitors; Lapatinib; Neratinib; Afatinib; Tucatinib;
Changing Natural History of HER2-Positive Breast Cancer Metastatic to the Brain in the Era of New Targeted Therapies
Keywords: لیپاتینیب; Brain metastases; Lapatinib; Outcome; TDM-1; Trastuzumab;
Structural and energetic basis for the molecular recognition of dual synthetic vs. natural inhibitors of EGFR/HER2
Keywords: لیپاتینیب; Cancer; Epidermal growth factor receptor (EGFR); Human epidermal growth factor receptor 2 (HER2); Lapatinib; (â)-epigallocatechin-3-O-gallate (EGCG); Molecular dynamics simulations;
Anti-HER-2 therapy following severe trastuzumab-induced cardiac toxicity
Keywords: لیپاتینیب; Diagnosis and management; HER2 positive breast cancer; Lapatinib; Trastuzumab-induced cardiac toxicity; Unusual presentation;
Southern surgical association articleAxillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative)
Keywords: لیپاتینیب; ALND; axillary lymph node dissection; BCT; breast-conserving therapy; CALGB; Cancer and Leukemia Group B; CNB; core needle biopsy; FNA; fine needle aspiration; HER2+BC; human epidermal growth factor receptor-2-positive breast cancer; L; lapatinib; NST; ne
ReviewThe efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: A systematic review and pooled analysis
Keywords: لیپاتینیب; Breast cancer; Brain metastasis; Lapatinib; Capecitabine; Response rate; Review;
Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer - Results from the prospective German TMK cohort study
Keywords: لیپاتینیب; Breast neoplasms; Cohort studies; Palliative care; Outpatients; Real-world data; Registries; ABC; advanced breast cancer; AGO; Arbeitsgemeinschaft Gynäkologische Onkologie; Bev; bevacizumab; C; cyclophosphamid; Cap; capecitabine; Car; carboplatin; CCI; C
Original ResearchPIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer
Keywords: لیپاتینیب; Buparlisib; Lapatinib; Breast cancer; HER2-positive; Trastuzumab-resistant;
Hydrophobic lapatinib encapsulated dextran-chitosan nanoparticles using a toxic solvent free method: fabrication, release property & in vitro anti-cancer activity
Keywords: لیپاتینیب; Nanoparticles; Dextran sulfate; Box-Behnken matrix; Lapatinib; Drug delivery; Anti-cancer;
Advances in the management of HER2-positive early breast cancer
Keywords: لیپاتینیب; Breast cancer; HER2; Trastuzumab; T-DM1; Neratinib; Pertuzumab; Lapatinib;
Systematic reviewConcurrent administration of anti-HER2 therapy and radiotherapy: Systematic review
Keywords: لیپاتینیب; Irradiation; Trastuzumab; Pertuzumab; T-DM1; Lapatinib; Concomitant;
Original ArticleSynergistic antitumor activity of regorafenib and lapatinib in preclinical models of human colorectal cancer
Keywords: لیپاتینیب; Regorafenib; Lapatinib; Targeted therapy; Combination chemotherapy; Colorectal cancer;
UPLC-ESI-MS/MS study of the effect of green tea extract on the oral bioavailability of erlotinib and lapatinib in rats: Potential risk of pharmacokinetic interaction
Keywords: لیپاتینیب; Green tea extract; Erlotinib; Lapatinib; UPLC-ESI-MS/MS; Pharmacokinetic interaction; Rat plasma;
Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia
Keywords: لیپاتینیب; DDI; drug-drug interaction; β-EST; β-estradiol; HLM; human liver microsomes; IV-IVE; in vitro-in vivo extrapolation; KI; kinase inhibitor; 4MU; 4-methylumbelliferone; LAP; lapatinib; NSB; non-specific binding; PAZ; pazopanib; PRO; propofol; REG; r
Summary of the 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
Keywords: لیپاتینیب; CVD; cardiovascular disease; HER2; human epidermal growth factor receptor 2; HF; heart failure; T-DM1; trastuzumab, pertuzumab, trastuzumab-emtansine; TKI; lapatinib; LV; left ventricular; ACE; angiotensin-converting enzyme (ACE) inhibitors; VEGF; vascula
Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials
Keywords: لیپاتینیب; Tumor-infiltrating lymphocytes; Neoadjuvant treatment; HER2-postive breast cancer; Pathologic complete response; Trastuzumab; Lapatinib;
Dermatologic Adverse Events Associated With Use of Adjuvant Lapatinib in Combination With Paclitaxel and Trastuzumab for HER2-Positive Breast Cancer: A Case Series Analysis
Keywords: لیپاتینیب; Adjuvant; HER2+; Lapatinib; Rash; Toxicity;
A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study)
Keywords: لیپاتینیب; Chemotherapy; Human epidermal growth factor receptor 2-positive; Lapatinib; Metastatic breast cancer; Treatment outcome;
Human epidermal growth factor antagonists and cardiotoxicity-A short review of the problem and preventative measures
Keywords: لیپاتینیب; Human epidermal receptor 2 (HER2); Left ventricular ejection fraction (LVEF); Trastuzumab; Pertuzumab; Lapatinib; Ado-trastuzumab (T-DM1);
Dual Blockade of HER-2 Provides a Greater Magnitude of Benefit in Patients With Hormone-Negative Versus Hormone-Positive Breast Cancer
Keywords: لیپاتینیب; HER-2 positive; Lapatinib; Neoadjuvant; PAM50; Trastuzumab;
Current challenges in HER2-positive breast cancer
Keywords: لیپاتینیب; Breast cancer; Dual targeting; HER2; Lapatinib; Neoadjuvant; Pertuzumab; Trastuzumab; Trastuzumab-emtansine;
Final overall survival analysis of a phase II trial evaluating vinorelbine and lapatinib in women with ErbB2 overexpressing metastatic breast cancer
Keywords: لیپاتینیب; Breast cancer; HER2; Lapatinib; Vinorelbine; Capecitabine; Overall survival;
Mechanisms of lapatinib resistance in HER2-driven breast cancer
Keywords: لیپاتینیب; Lapatinib; Resistance; ErbB2/HER2; Breast cancer;
Métastases cérébrales de cancer du sein : traitements systémiques
Keywords: لیپاتینیب; Métastases cérébrales; Cancer du sein; Trastuzumab; Lapatinib; Chimiothérapie; Anti-HER-2+; TraitementBrain metastases; Breast cancer; Trastuzumab; Lapatinib; Chemotherapy; Anti-HER-2+; Treatment
Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: A randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie
Keywords: لیپاتینیب; Gastric cancer; HER2; EGFR; Lapatinib;
Spectroscopic and molecular docking studies of binding interaction of gefitinib, lapatinib and sunitinib with bovine serum albumin (BSA)
Keywords: لیپاتینیب; Gefitinib; Lapatinib; Sunitinib; Bovine serum albumin; Binding interaction
Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer
Keywords: لیپاتینیب; Tykerb/Tyverb Evaluation After Chemotherapy (TEACH) trial; Health related quality of life; HRQOL; Adjuvant breast cancer; Human Epidermal Growth Factor Receptor (HER2); HER2 positive; Early breast cancer; Lapatinib; Placebo; SF-36
HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer
Keywords: لیپاتینیب; HER family mutation; Kinase domain; Lapatinib; Drug resistance; Biomarker; TKI; tyrosine kinase inhibitors;
Synthesis, physicochemical and biological evaluation of technetium-99m labeled lapatinib as a novel potential tumor imaging agent of Her-2 positive breast cancer
Keywords: لیپاتینیب; Lapatinib; Her-2 receptor; Technetium; Radiopharmaceutical; SKOV-3; Her-2; Human Epidermal Growth Factor Receptor 2; IHC; immunohistochemical; FISH; fluorescent in situ hybridisation; CISH; chromogenic in situ hybridisation; HPLC; high-performance liquid
Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer
Keywords: لیپاتینیب; Trastuzumab; Lapatinib; Chemotherapy-free; HER2-enriched; Microarray; Signature; CT; chemotherapy; total HER2; (H2T); p95HER2; (p95); PP; persistence on protocol; CR; complete remission; PR; partial remission; SD; stable disease; PD; progressive disease;